A looming anti-China biotechnology bill has spooked U.S. life sciences companies, according to a new report.
The report by the China-based L.E.K. Consulting quantifies what until now has been mostly a vibe check. At this year’s Biotechnology Innovation Organization’s international conference, multiple biotech companies told STAT they plan to switch from striking deals with Chinese companies to U.S.-based drug manufacturers, even though doing so will be more costly, and the BIOSECURE Act is still just a proposal, albeit one with traction in Congress.
“The Act, regardless of passage, is likely to reshape how the global biopharma industry operates,” the report states.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.